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Abstract Chronic tissue injury with fibrosis results in
the disruption of tissue architecture, organ dysfunction
and eventual organ failure. Therefore, the development
of effective anti-fibrotic therapies is urgently required.
During fibrogenesis, complex interplay occurs between
cellular and extracellular matrix components of the
wound healing response. Integrins, a family of trans-
membrane cell adhesion molecules, play a key role in
mediating intercellular and cell-matrix interactions.
Thus, integrins provide a major node of communication
between the extracellular matrix, inflammatory cells, fi-
broblasts and parenchymal cells and, as such, are inti-
mately involved in the initiation, maintenance and reso-
lution of tissue fibrosis. Modulation of members of the αv
integrin family has exhibited profound effects on fibrosis in
multiple organs and disease states. In this review, we dis-
cuss the current knowledge of the mechanisms of αv-
integrin-mediated regulation of fibrogenesis and show that
the therapeutic targeting of specific αv integrins represents
a promising avenue to treat patients with a broad range of
fibrotic diseases.
Keywords Integrins . Fibrosis . TGFβ . Extracellular
matrix . Myofibroblasts
Introduction
Chronic tissue injury with fibrosis results in the disruption of
tissue architecture, organ dysfunction and eventual organ fail-
ure. Although fibrosis represents a massive healthcare burden
worldwide, currently available therapeutic options are severe-
ly limited and organ transplantation is, in many cases, the only
effective treatment for end-stage fibrotic disease. However,
limited donor organ availability, high cost and co-
morbidities in potential recipients mean that, on a global scale,
organ transplantation can only be offered to a small percentage
of patients suffering from the complications of fibrosis. The
development of effective anti-fibrotic therapies is therefore
essential to improving our patient care.
Fibrogenesis involves a complex interplay between the in-
flammatory, epithelial, myofibroblast and extracellular matrix
(ECM) components of the wound healing response
(Henderson and Iredale 2007; Varga and Abraham 2007).
The pericellular ECM, in particular, represents a highly dy-
namic environment known to exert profound influences on
cell behaviour. As transmembrane proteins, the integrin family
of cell adhesion molecules mediates many key cell–cell and
cell-matrix interactions during fibrosis. Integrins represent a
major node of communication between the ECM, inflamma-
tory cells, fibroblasts and parenchymal cells and are intimately
involved in the initiation, maintenance and resolution of tissue
fibrosis. Integrins are composed of non-covalent α/β hetero-
dimers of which there are 24 known members in humans and
comprise 18 different α subunits and 8 β subunits. They can
translate extracellular signals, resulting in a wide range of
downstream effects on cell adhesion, migration, proliferation,
differentiation and apoptosis (Hynes 2002). Of particular note
is the αv subunit, which forms heterodimers with the β1, β3,
β5, β6 or β8 subunits. As outlined in Table 1, modulation of
various members of the αv integrin family has exhibited
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profound effects on fibrosis in multiple organs and disease
states. In this review, we will discuss the ways in which αv
integrins regulate the fibrotic process and show that the ther-
apeutic targeting of specific αv integrins represents a promis-
ing avenue for treating patients with a broad range of fibrotic
diseases.
Regulation of TGFβ activity by αv integrins
In addition to their direct effects on cellular proliferation and
survival, integrins may also potentiate signals from soluble
growth and survival factors. Secreted transforming growth
factor beta (TGFβ) is a key regulator of fibrosis in multiple
organs (Ignotz and Massagué 1986; Roberts et al. 1986;
Hynes 2002; Leask and Abraham 2004). The three mamma-
lian isoforms of TGFβ are all synthesised as precursor pro-
teins, which are then processed by proteolytic cleavage within
the endoplasmic reticulum. They are subsequently assembled
as a non-covalent Bsmall latent complex^ of a disulfide-linked
homodimer of the mature cytokine (a short C-terminal frag-
ment), which is encased within a disulfide-linked homodimer
of a larger amino terminal fragment called the latency-
associated peptide (LAP), forming the Bsmall latent complex^.
In this form, the associated LAP homodimer prevents the ma-
ture C-terminal fragment from binding to its receptors by
holding it in a conformation distinct from that of the free
dimer. This Bsmall latent complex^ is further modified in the
endoplasmic reticulum by disulfide linkage to another family
of proteins, namely latent TGFβ binding proteins, which upon
secretion are themselves chemically cross-linked to the ECM,
for storing and tethering TGFβ in a latent form in the extra-
cellular space. Tissue forces such as cellular contraction dis-
rupt the latency cage, releasing the mature dimer and enabling
it to activate TGFβ receptors. Much of the regulation of
TGFβ biology thus occurs at the level of extracellular activa-
tion of this stored latent complex (Gleizes et al. 1997; Munger
et al. 1997).
The three isoforms of TGFβ, namely TGFβ-1, -2 and -3,
appear to have overlapping functions. All mediate their ef-
fects, at least in part, through the intracellular SMAD pathway
and, of the three, TGFβ1 is the most widely involved in
fibrogenesis. αv integrins have been demonstrated to play a
key role in the activation of latent TGFβ1 and TGFβ3 (Annes
et al. 2002). Specifically, all five integrins have been shown to
interact with a linear arginine-glycine-aspartic acid (RGD)
motif present in the LAP, activating latent TGF-β (Munger
et al. 1999; Mu et al. 2002; Asano et al. 2006; Wipff et al.
2007). Inhibition and blockade of αvβ6 and αvβ8
phenocopies all have the developmental effects of loss of
TGFβ1 and 3 (Aluwihare et al. 2008), suggesting that these
two integrins are required for most or all important roles of
these TGFβ isoforms during development. However, the
mechanisms of TGFβ activation underlying its contribution
to adult tissue pathology are less well understood.
The actin cytoskeleton also plays a role in the activation of
TGFβ1, as demonstrated by the inhibition of TGFβ activity
following the blockade of actin polymerisation (Munger et al.
1997) or the inhibition of Rho kinase (Jenkins et al. 2006).
The mechanical force generated by integrin-mediated regula-
tion of the actin cytoskeleton is a common mechanism for
activating latent TGFβ1 (Shi et al. 2011). Shi et al. (2011)
reported that mere complex formation between integrin
αvβ6 and the prodomain of TGFβ1 is insufficient for its
release, with the activation of TGFβ1 requiring a further
force-dependent unfastening of a Bstraitjacket^ that encircles
each growth factor dimer. This is attributable to the LAP
prodomain altering the conformation of TGFβ1 and effective-
ly shielding TGFβ1 from recognition by receptors.
One cell type intrinsically involved in organ scarring is the
myofibroblast that provides a major source of ECM proteins
during fibrogenesis (Klingberg et al. 2012). The precise origin
of myofibroblasts is unclear with studies indicating
transdifferentiation from both local and influxing cells in re-
sponse to growth factors and mechanical tension (Munger
et al. 1999; Aluwihare et al. 2008; Iwaisako et al. 2014).
Highly contractile cells, myofibroblasts express several αv
integrins that transmit the force generated by the actin cyto-
skeleton to the ECM (Fig. 1). Myofibroblast αv integrins are
able to liberate and thereby activate TGFβ1 deposits in the
ECM via mechanical force. Further insights into this process
have been provided by Klingberg et al. (2014) who demon-
strated, through a series of in vitro experiments, that latent
ECM-bound TGFβ1 is primed by the stiffening of the sur-
rounding ECM, such that greater amounts are released com-
pared with a relaxed ECM (Klingberg et al. 2014). Therefore,
prior to force-mediated activation of TGFβ1, myofibroblasts
actively re-organise the ECM, increasing the bioavailability of
the bound latent TGFβ1 complex.
Role of individual αv integrins during fibrogenesis
αvβ1
Study of the function of αvβ1 during fibrogenesis has been
challenging. The β1 integrin dimerises with multiple α sub-
units and, therefore, interrogation of the role of αvβ1 has not
been possible by using standard transgenic mouse approaches.
This has further been hampered by a lack of specific function-
blocking antibodies or small molecule antagonists. Recently,
however, a small molecule inhibitor of αvβ1, which is highly
specific and potent in its activity, has been developed (Reed
et al. 2015).
To develop this αvβ1 small molecule inhibitor, Reed et al.
(2015) used the known base compound of αv and combined
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this with their previously described sulfonamidoproline moi-
ety, which binds to the β1 subunit of α2β1 (Miller et al.
2009). The efficacy of a set of synthesised compounds in bind-
ing to individual αv integrin heterodimers and inhibiting cell
adhesion was tested by using a panel of cell lines and ligands.
Two compounds (c6 and c8) were found to achieve potent and
specific inhibition of αvβ1 in vitro, supported by the loss of
adhesion to the αvβ1 ligand, fibronectin. In cell adhesion as-
says in vitro, the c8 compound efficiently blocked the adhesion
of fibroblasts to TGFβ1 LAP, a result that was not replicated by
using antibodies to αvβ3, αvβ5, αvβ6 or αvβ8. This demon-
strated that αvβ1 is the predominant fibroblasticαv integrin on
fibroblasts mediating adhesion to the TGFβ1 LAP. Further in
vitro characterisation, by using primary murine hepatic stellate
cells and human lung fibroblasts, showed that c8 could potently
and specifically inhibit TGFβ activation.
Using two murine models of fibrosis, namely carbon
tetrachloride-induced liver fibrosis and bleomycin-induced
lung fibrosis, Reed et al. (2015) demonstrated in vivo that
the systemic delivery of c8 reduces fibrosis. Moreover, the
degree of protection is comparable to that seen in a previous
study, which conditionally deleted all αv integrins on
myofibroblasts (Henderson et al. 2013) providing further ev-
idence that αvβ1 is, to a large degree, responsible. Direct
evidence of suppressed TGFβ signalling through reduced
phosphorylation of the TGFβ intracellular signalling effector,
Smad3, further suggests that this antifibrotic effect is attribut-
able to the inhibition of αvβ1-mediated TGFβ activation.
αvβ3 and αvβ5
Expression of αvβ3 and αvβ5 is upregulated during cardiac
and skin fibrosis and both heterodimers have been reported to
activate TGFβ1 signalling in vitro (Asano et al. 2004; Jenkins
et al. 2006; Shi et al. 2011; Sarrazy et al. 2014). Treatment of
primary cultures of scleroderma fibroblasts with anti-αvβ3
and anti-αvβ5 antibodies reduced type I procollagen expres-
sion, suggesting an anti-fibrotic effect (Asano et al. 2005,
2006; Miller et al. 2009). Furthermore, blockade of αvβ3 on
culture-activated liver myofibroblasts inhibited their prolifer-
ation and increased apoptosis (Zhou et al. 2004).
However, the in vivo effects of αvβ3 and αvβ5 inhibition
studied via genetic depletion and pharmacological blockade
are less consistent. A β3/β5 double-knockout mouse was not
protected from bleomycin-induced lung fibrosis, indicating
the possible compensatory involvement of other integrins
(Atabai et al. 2009). In the thioacetamide (TAA) and bile duct
ligation (BDL) liver fibrosis models, αvβ3 inhibition
Fig. 1 Complex interplay of αv-integrin-mediated regulation of tissue
fibrosis.αv integrins (β1,β3,β5,β8) expressed on fibroblasts andαvβ6
expressed on epithelia activate transforming growth factor beta (TGFβ)
through their interaction with a linear arginine-glycine-aspartic acid
(RGD) binding motif present on the latency-associated peptide (LAP) in
the extracellular matrix (ECM). TGFβ released from the ECM by injured
epithelia might directly signal to the myofibroblast to promote further
ECM production. Furthermore, αv integrins on myofibroblasts can re-
lease active TGFβ from the ECM; this TGFβ then signals in an autocrine
manner to drive further ECM production by myofibroblasts
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augmented rather than reduced collagen levels (Patsenker
et al. 2009). Furthermore, the αvβ3 antagonist Cilengitide
failed to show any anti-fibrotic effects in two distinct models
of liver fibrosis (BDL and TAA-induced injury), instead sig-
nificantly increasing collagen deposition (by 31 % in BDL
and 27% in TAA) and up-regulating pro-fibrotic gene expres-
sion (Patsenker et al. 2009). Using a mouse model of stiff skin
syndrome, which is caused by a fibrillin-1 mutation and leads
to the development of aggressive skin fibrosis, Gerber et al.
(2015) reported thatβ3 integrin is expressed on systemic scle-
rosis dermal fibroblasts.
In the context of cardiac fibrosis, αvβ3 and αvβ5 have
recently been shown to compensate for each other’s function
with regard to TGFβ1 activation and myofibroblast differen-
tiation (Sarrazy et al. 2014). Through a series of in vitro stud-
ies by using transfection and short hairpin RNA to overex-
press or knockdown β3 and β5 on human cardiac fibroblasts,
the knockdown of one resulted in the elevated expression of
the other. Conversely, the overexpression of either integrin
reduced the expression of the other. Individual knock-down
of β3 and β5 integrins only moderately reduced the release of
active TGFβ1 and α-smooth muscle actin (α-SMA) expres-
sion, whereas the simultaneous knock-down of both integrins
led to a significant reduction in TGFβ1 release and α-SMA
expression compared with controls.
αvβ6
Expression of αvβ6 integrin in the uninjured lung, liver and
kidney is generally low but, in the context of inflammation
and fibrosis, αvβ6 levels increase (Munger et al. 1999; Asano
et al. 2005; Wang et al. 2007). Expression of αvβ6 is restrict-
ed to cells of the epithelial lineage (Breuss et al. 1995) and
mediates the activation of TGFβ1 and TGFβ3 by direct bind-
ing of the integrin to the LAP (Annes et al. 2002) at epithelial
surfaces (Munger et al. 1999; Shi et al. 2011). Cells expressing
αvβ6 activate TGFβ1 in vitro and this can be completely
inhibited by β6-blocking antibodies. Further, similar to mice
homozygous for a null mutation of TGFβ1, pan-β6 integrin
subunit knockout mice develop exaggerated inflammatory re-
sponses in the lungs and skin, albeit less severe than in TGFβ1
null mice (Huang et al. 1996).
In patients with fibrotic liver disease secondary to a variety
of aetiologies (primary biliary cirrhosis, alcohol-induced, hep-
atitis B and C), integrin αvβ6 mRNA expression is increased
and has been found to correlate with fibrosis stage in hepatitis
C (Popov et al. 2008). Expression of αvβ6 in human chronic
dermal wounds is strongly upregulated and, in the primate
lung, alveolar epithelial cell αvβ6 expression is rapidly in-
duced following lung injury (Breuss et al. 1993). In mice
expressing the cytokeratin 14 promoter, driving constitutive
αvβ6 expression in epidermal basal cells, spontaneous chron-
ic skin wounds develop surrounded by fibrotic tissue
(Häkkinen et al. 2004). Conversely, in aged β6-knockout
mice, a significant delay in wound healing is seen compared
with aged-matched controls (AlDahlawi et al. 2006), suggest-
ing an important role in the timely resolution of injury.
In the lung, β6 null mice develop exaggerated inflammation
in response to bleomycin treatment but are dramatically protected
from subsequent pulmonary fibrosis (Munger et al. 1999). In β6
knockout mice treated with bleomycin, microarray analysis of
the lungs identified a large group of TGFβ-inducible genes that
were induced at substantially lower levels than in wild-type con-
trol mice (Kaminski et al. 2000; Atabai et al. 2009).
Administration of anti-αvβ6 antibodies was able to attenuate
bleomycin-induced pulmonary fibrosis with a concomitant re-
duction in TGFβ activity (Horan et al. 2008; Patsenker et al.
2009). Further, β6 inhibition, induced both by genetic knockout
and blockade with anti-αvβ6 antibodies, was protective in
radiation-induced pulmonary fibrosis (Puthawala et al. 2008;
Patsenker et al. 2008). However, high doses of anti-αvβ6mono-
clonal antibody resulted in lung inflammation, similar to αvβ6-
null mice (Puthawala et al. 2008; Sarrazy et al. 2014). A
humanised monoclonal antibody targeting αvβ6, STX-100,
has been developed and is currently being evaluated in phase 2
clinical trials for the treatment of idiopathic pulmonary fibrosis.
Recently, using both pharmacological and genetic inhibition
of theαvβ6 integrin,Madala et al. (2014) demonstrated that, in a
TGFα model of pulmonary fibrosis, the activation of the αvβ6/
TGFβ pathway has a secondary effect on pleural fibrosis.
Doxycycline-induced overexpression of TGFα in lung epithelia
generates progressive lung fibrosis. With this model of lung fi-
brosis, the authors demonstrated that the activation of the αvβ6/
TGFβ pathway occurred following fibrosis development.
Inhibition of αvβ6 by using function-blocking antibodies in
established lung fibrosis in TGFα-overexpressing mice was able
to attenuate the continuation of pleural thickening and decline in
lung function. Further, in TGFα-overexpressing mice with
8 weeks of fibrosis induction, genetic ablation of β6 limited the
histological and physiological pulmonary changes; however, fi-
brosis was still significant. This suggests that in this specific
model of TGFα-induced lung fibrosis, the effective abrogation
of fibrosis might require the targeting of multiple pathways in
order to limit fibrogenesis and altered lung physiology.
Integrin αvβ6 has also been shown to play an important
role in the progression of biliary fibrosis. In the BDLmodel of
acute biliary fibrosis, Wang et al. (2007) demonstrated that
bile duct obstruction markedly increased cholangiocyte
αvβ6 expression and, moreover, that biliary fibrosis was re-
duced in β6 integrin null mice by 50 % compared with wild-
type controls. Administration of an αvβ6-blocking antibody
significantly decreased acute biliary fibrosis following BDL
(Wang et al. 2007). Pharmacological inhibition of αvβ6 by
using the small molecule inhibitor EMD527040 also inhibited
biliary fibrosis. In BDL rats and in Mdr2 (abcb4)−/− mice (a
model of bile duct obstruction), treatment with EMD527040
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during established fibrosis reduced bile duct proliferation and
peribiliary collagen deposition by between 40 and 50 %, de-
creased pro-fibrotic gene expression and up-regulated
fibrolytic genes (Patsenker et al. 2008). Furthermore, αvβ6
has recently been reported to be expressed on and to regulate
the function of hepatic progenitor cells (Peng et al. 2015).
Genetic modulation and pharmacological inhibition of αvβ6
activity during chronic liver injury strongly suppressed pro-
genitor cell proliferation in vitro. In vivo, this led to a marked
attenuation of biliary fibrogenesis and protection from
fibrosis-associated liver cancer (Breuss et al. 1993; Peng
et al. 2015).
In renal fibrosis, the regulatory role of αvβ6 has been
investigated by using both function-blockingαvβ6 antibodies
and the mouse model of Alport syndrome (Col4A3−/− mice)
combined withβ6 integrin knockout mice (Hahm et al. 2007).
Treatment with αvβ6-blocking antibody prevented the accu-
mulation of activated fibroblasts and reduced interstitial col-
lagen matrix deposition. Genetic ablation of β6 integrin, in a
model of Alport syndrome (Col4A3−/−mice), resulted in sim-
ilar effects on renal fibrosis. These findings were recapitulated
in the unilateral ureteric obstruction model of renal fibrosis
(Ma et al. 2003). Although these data suggest a strong regu-
latory role for αvβ6 in renal fibrosis, the blockade of αvβ6
activity following renal transplantation has been reported to
increase significantly the acute rejection of the transplanted
organ (Lo et al. 2013).
αvβ8
Mice with β8 subunit knockout exhibit vascular development
defects similar to those seen in TGFβ1 null mice, with a
number dying mid-gestation (Zhu et al. 2002). Of those that
survive to birth, death occurs soon after from brain haemor-
rhage, possibly because of the loss of the developmental vas-
cular effects of TGFβ1. Furthermore, many of these mice
have a cleft palate, a prominent feature in TGFβ3 knockout
mice suggesting an important role for αvβ8 in activating
TGFβ3 in vivo, in addition to TGFβ1 activation in vivo
(Proetzel et al. 1995; Huang et al. 1996).
Both αvβ8 and αvβ6 bind to the same RGD sequence in
the LAPs of TGFβ1 and TGFβ3, although the mechanism by
which they activate TGFβ1 has been shown to differ.Whereas
αvβ6 requires direct cell–cell contact to activate TGFβ1,
αvβ8-mediated activation requires the extracellular
localisation of β8, in addition to metalloprotease (MMP) ac-
tivity. Furthermore, in vitro studies have shown thatαvβ8 can
release active TGFβ1 into the media (Mu et al. 2002; Popov
et al. 2008). Unlike αvβ6, metalloprotease inhibitors reduce
αvβ8-mediated TGFβ1 activation and in vitro transfection
studies have demonstrated a specific role for MT1-MMP
(MMP14) in this process (Breuss et al. 1993; Mu et al.
2002). Araya and colleagues (2007) transfected primary
airway fibroblasts with MMP14 short interfering RNA
(siRNA), inhibiting 70 % of its surface expression leading to
a marked inhibition of αvβ8-mediated activation of TGFβ.
This suggests that αvβ8 activates TGFβ1 by presenting LAP
complexes to cell-surface MMPs that, in turn, degrade the
LAP, releasing free TGFβ1.
In chronic obstructive pulmonary disease (COPD) patients,
the degree of airway wall fibrosis has been shown to correlate
with αvβ8 expression on isolated airway fibroblasts (Araya
et al. 2007). When incubated with interleukin-1β (IL-1β),
lung fibroblasts isolated from COPD patients showed en-
hanced αvβ8-dependent TGFβ activation, collagen expres-
sion and pro-inflammatory gene expression compared with
normal lung fibroblasts (Araya et al. 2007). Further investiga-
tion in vitro showed that the autocrine αvβ8-mediated activa-
tion of TGFβ1 contributed to the pro-fibrogenic differentia-
tion of COPD fibroblasts, as demonstrated by using siRNA to
knockdown β8 expression, leading to reduced αSMA and
collagen I expression. However, this intervention inhibited
only half of the total TGFβ activation when compared with
a TGFβ-blocking antibody. In murine airway fibrosis, condi-
tional deletion of lung fibroblast αvβ8 inhibited airway fibro-
sis in both IL-1β and ovalbumin-induced models (Kitamura
et al. 2011). Furthermore, depletion of αvβ8 on cultured
mouse lung fibroblasts reduced TGFβ1 activation (Kitamura
et al. 2011).
In children with biliary atresia (a pediatric cholestatic dis-
ease), immunohistochemical analysis of liver biopsies has
shown increased expression of αvβ8 integrin compared with
healthy controls (Iordanskaia et al. 2014). Interestingly, dys-
regulation of MMP14 has also been reported in both human
and animal models of biliary atresia (Iordanskaia et al. 2013).
This suggests that the activation of TGFβ in the setting of
biliary atresia may in part be mediated through both increased
αvβ8 expression and altered expression of MMP14. Further
studies will be required to explore this in more depth.
Concluding remarks
The molecular pathways that regulate TGFβ signalling are
attractive targets for novel anti-fibrotic therapies. However,
currently available methods of pan-TGFβ inhibition
target all three mammalian isoforms and, because of the crit-
ical role of TGFβ in normal tissue homeostasis, this has led to
serious concerns about potential side effects. For example,
given its anti-proliferative effect on most epithelial cell types,
there is a risk that TGFβ1 inhibition could promote carcino-
genesis. This is particularly relevant in advanced liver fibrosis,
where most hepatocellular carcinomas originate from cirrhotic
tissue. Additionally, because of the critical immunosuppres-
sive role of TGFβ1 (Shull et al. 1992; Kulkarni et al. 1993;
Yaswen et al. 1996), pan-TGFβ blockade can lead to
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excessive autoimmunity and inflammation, which could be
highly deleterious in a fibrotic organ with limited functional
reserve. Therefore, the inhibition of specific αv integrin sub-
units might allow a more refined and targeted approach to
TGFβ pathway inhibition, providing the desired anti-fibrotic
effects but with fewer undesirable side effects.
In recent years, it has become apparent that αv integrins
play a key role in fibrosis inmultiple organs. Abundant in vivo
data are now available demonstrating critical regulatory roles
for αv integrins expressed on multiple cell types during the
fibrotic process. The component parts of tissue fibrogenesis
are exquisitely complex and these studies highlight the impor-
tant cross-talk between epithelia, myofibroblasts and the cells
of the immune system during the development and resolution
of fibrosis. Strategies to manipulate αv integrins, such as an-
tibody blockade and small molecule inhibitors, will hopefully
yield effective anti-fibrotic therapies in the future.
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